Alejandro M. Mayer, Ph.D.

Professor
Downers Grove, IL

Home / Academics / Our Faculty / Alejandro M. Mayer, Ph.D.

About

HISTORY OF CURRENT AND PREVIOUS ACADEMIC/PROFESSIONAL APPOINTMENTS

2000-current    Professor, Department of Pharmacology, College of Graduate Studies, Chicago College of Osteopathic Medicine, Chicago College of Pharmacy, College of Dental Medicine Illinois, Chicago College of Health Science, Chicago College of Optometry, Midwestern University, Downers Grove, Illinois

1995-2000       Associate Professor, Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, Illinois

1993-1995       Assistant Professor, Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, Illinois

1990-1993       Research Assistant Professor, Department of Physiology, Louisiana State University Medical Center, New Orleans, Louisiana

1988-1990       Research Scientist, National Academy of Medicine and National Research Council, Buenos Aires, Argentina

1987-1988       Adjunct Assistant Professor, Department of Biology, University of California Santa Barbara, Santa Barbara, California

1985-1987       Postdoctoral Fellow, Department of Biology, University of California Santa Barbara, Santa Barbara, California

 

Title
Professor

Campus
Downers Grove, IL

College
Chicago College of Optometry
Chicago College of Osteopathic Medicine
College of Dental Medicine-Illinois
College of Graduate Studies - IL

Department
Pharmacology

Program
Dental Medicine
Optometry
Osteopathic Medicine

Call My
Office

630-515-6951

Send Me
a Message

amayer@midwestern.edu

Education

Northwestern University | 2008 | M.S.Ed.
University of Buenos Aires
Argentina | 1980 | Ph.D.

Courses Taught

SYNOPSIS OF TEACHING EXPERIENCE AND EDUCATIONAL PROGRAM RESPONSIBILITIES (1993-2019)

During the past 27 years, as a faculty member of the Department of Pharmacology at the College of Graduate Studies (CGS), my teaching responsibilities have included lectures and clinical case studies to students from Chicago College of Osteopathic Medicine (CCOM),   Chicago College of Pharmacy (CCP),  Chicago College of Health Sciences (CHP), College of Dental Medicine Illinois (CDMI) and Chicago College of Optometry (CCO), in the following areas as classified in  Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition: Drugs acting on the central nervous system: local anesthetics; Autacoids: drug therapy of inflammation: nonsteroidal anti-inflammatory agents, corticosteroids and drugs used for the treatment of arthritis; Chemotherapy of microbial diseases: drugs for used in the treatment of tuberculosis and leprosy, antivirals (including anti-HIV agents), and antifungal agents; Chemotherapy of neoplastic diseases: antineoplastic agents; Drugs used for immunomodulation: immunosuppressive and immune stimulant agents; Drugs acting on the blood and blood forming organs: hematopoietic agents, anticoagulant, thrombolytic and antiplatelet drugs; Hormones and Hormone Antagonists: adrenocortical steroids and synthetic analogs.  I have served as Course Director of CCOM/CCP/CHS/CCO Pharmacology courses in numerous years. In addition, from 1994-2011, I contributed a two-hour Marine Pharmacology lecture to CCP students participating in the Topics in Advanced Medicinal Chemistry course. Finally, I have served as the course Director of a 20-hour Medical Spanish elective, which has been offered during the Fall and Spring quarters to medical, pharmacy and health science students from 1994-2017.

Research

Project I:

Marine pharmaceuticals: marine natural products as pharmacological agents for the modulation of inflammatory and neurotoxic mediators generated by activated microglia   Neuroinflammatory conditions are complex and poorly understood disease processes which are hypothesized to involve microglia or brain macrophages.  When microglia become activated they release cytotoxic substances (reactive oxygen intermediates, eicosanoids, cytokines and metalloproteinases) which are cytotoxic to brain cells.  Microglia are believed to be involved in human brain disorders, such as postischemic brain injury, HIV encephalopathy, Parkinson's disease, Alzheimer's disease and multiple sclerosis. Present therapies of these inflammatory conditions are based on steroids and nonsteroidal anti-inflammatory therapies which are associated with a high incidence of unsatisfactory toxicity and poor efficacy.  Marine anti-inflammatory natural products may constitute a novel source of lead compounds to enable the development of a new generation of drugs for the clinical management of neurological diseases. The Mayer lab which has been studying marine natural products at CCOM for the past 27 years, has become a contributor to the discovery of novel marine antineuroinflammatory compounds, and has contributed the first two patents assigned to Midwestern University (US patents # 6,3887,916 and # 6,602,881) in 2002 and 2003, respectively. Dr. Mayer's marine pharmaceutical's website maintained with the assistance of CCP students and the IT Department is currently # 1 in Google and has been visited over 41,000 times. Dr. Mayer served as the Editor-in-Chief of the journal Marine Drugs from January 2014 till July 2018.

 

Project II:

Marine toxicology: immunotoxicology of marine and freshwater-derived cyanobacterial lipopolysaccharides. Cyanobacteria or blue-green algae, are photosynthetic prokaryotes that represent one of the oldest life forms and are a rich source of natural products with unique pharmacological and toxicological properties, which possess neuroprotective, cytotoxic, antibacterial, antifungal, antiviral and anti-inflammatory properties. Cyanobacterial LPS differs from Gram-negative bacteria both chemically and biologically. The Mayer lab has been studying the immunotoxicology of cyanobacterial lipopolysaccharides since 2011 and has shown that the cyanobacterial LPS’s elicit release of superoxide anion, thromboxane B2, cytokines, chemokines, and matrix metalloproteinase-9  by rat microglia in vitro. 

Publications

Recent list of publications

Z. Memedovski, E. Czerwonka, J. Han, J. Mayer, M. Luce, L. C. Klemm, M. L. Hall, and A.M.S. Mayer. Classical and Alternative Activation of Rat Microglia treated with ultrapure Porphyromonas gingivalis Lipopolysaccharide in vitro. Prepared for submission,  April  2020.

Mayer, A.M.S., A.J. Guerrero, A. D. Rodríguez, O.  Taglialatela-Scafati, F. Nakamura and N. Fusetani. Marine Pharmacology in 2014–2015: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Marine Drugs 18(5), 2019. PMID: 31861527

Swanson-Mungerson, M., P. Williams, J. Gurr, R.  Incrocci, V.  Subramaniam, K.  Radowska, M. L. Hall, and A.M.S. Mayer. Biochemical and Functional Analysis of Cyanobacterium Oscillatoria sp. LPS on Human Monocytes. Toxicological Sciences  171(2):421-430, 2019. PMID: 31271425

L. C. Klemm, E. Czerwonka, M. L. Hall, P. Williams, and A.M.S. Mayer. Cyanobacteria Scytonema javanicum and Scytonema ocellatum lipopolysaccharides elicit release of superoxide anion, matrix-metalloproteinase-9, cytokines and chemokines by rat microglia in vitro. TOXINS 10: 130, 2018.  PMID: 29561785 

Mayer, A.M.S., A. D. Rodríguez, O.  Taglialatela-Scafati and N. Fusetani.  Marine Pharmacology in 2012-2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Marine Drugs 15 (9): 273, 2017.  PMID: 28850074

M. Swanson-Mungerson, R. Incrocci, V. Subramaniam, P. Williams, M. L. Hall, and A.M.S. Mayer. Effects of cyanobacteria Oscillatoria sp. lipopolysaccharide on B cell activation and Toll-like receptor 4 signaling. Toxicology Letters 275: 101-107, 2017. PMID: 28499610

Mayer, A.M.S., J. Murphy, D. MacAdam, C. Osterbauer, I. Baseer, M. L. Hall, D. Feher and P. Williams. Classical and alternative activation of cyanobacterium Oscillatoria sp. lipopolysaccharide-treated rat microglia in vitro. Toxicological Sciences 149(2):484-95, 2016

Avilés, E, Prudhomme, J., Le Roch, K.G., Franzblau, S.G., Chandrasena, K., Mayer, A.M.S., and A.D. Rodríguez. Synthesis and preliminary biological evaluation of a small library of hybrid compounds based no Ugi isocyanide multicomponent reactions with a marine natural product scaffold. Bioorganic & Medicinal Chemistry Letters  25(22):5339-43, 2015

Mayer, A.M.S., M. L. Hall, M. Holland, C. De Castro, A. Molinaro, M. Aldulescu, J. Frenkel, L. Ottenhoff, D. Rowley and J. Powell.  Vibrio vulnificus M06-24/O  lipopolysaccharide stimulates  superoxide anion, thromboxane B2, matrix metalloproteinase-9, cytokine and  chemokine release by rat microglia in vitroMarine Drugs 12:1732-1756, 2014.

C. Jiménez-Romero, A.M.S. Mayer and A.D. Rodríguez. Dactyloditerpenol acetate, a new prenylbisabolane-type diterpene from Aplysia dactylomela with strong anti-neuroinflammatory activity. Bioorganic & Medicinal Chemistry Letters 24: 344-348, 2014.

 

Organizations

 2016               Member: IUPHAR, International Union of Basic and Clinical Pharmacology

 2015               Member: Council of Scientific Editors

 1994               Member: American Society for Pharmacology and Experimental Therapeutics

 1991               Member: American Association for the Advancement of Science

Grants

 Resubmission of R15 Grant Proposal titledCyanobacterial LPS and brain microglia activation  

In order to resubmit this R15 Grant proposal with a new approach as requested by the NIH Study Section reviewers, we have been working to establish cultures of de-identified human brain tissue provided by Cook County Hospital and developing methods to isolate microglia from human brain cultures. So far my laboratory at MWU has received 4 de-identified human brain tissue biopsies from Dr. Sierens, at the John J. Stroger Jr., Hospital of Cook County, Chicago. The de-identified human brain biopsies received were placed in tissue culture. Interestingly, 3 of 4 brain biopsies developed into cell cultures, which are currently growing in my laboratory in Science Hall 308, Midwestern University Downers Grove campus.  In the summer of 2018, Tina Moazezi, CCOM 2021, KAS summer fellow in Dr. Mayer’s lab identified the cells types in one of the human brain tissue cultures by immunohistochemistry.  In the summer of 2019,  Zylfi Memedovski CCOM 2022, continued to work to confirm the presence of human microglia in one of the brain cultures using three microglia-specific antibodies. If presence of human microglia is confirmed, we plan to resubmit our R15 Grant Proposal with a revised approach based on the human microglia model.

 

  • Title: Investigation of the Effects of Cyanobacteria Lipopolysaccharide on Human Immune Cell Activation and Function                                                

Agency:                                           MWU’s One Health Stimulus Research Award

Amount:                                           Total: $10,000

Dates:                                              7/1/2016-6/30/2018          

Principal Investigator:                   Michelle Swanson-Mungerson    

Co- Principal Investigator:            Mayer, Alejandro

Status:            Submitted: 3/18/2016. Funded on 4/19/2016

 

OTHER GRANT PROPOSALS

  • Title: Native American Botanical Medicines-Cancer, Depression and  Inflammation

                                                        

Agency: NIH P50 Program Project Grant with University of Mississippi & Henry Ford Health System

Amount: Total: $1,182,660 over 5 years. $793,730 (direct), $388,930 (indirect).

Dates:                                              7/1/2015-6/30/2020          

Principal Investigator:                   Dr. Frederick Valeriote, Henry Ford Health System       

Co-Investigator:                             Mayer, Alejandro

Status:                                             Submitted: 6/6/2014. Grant proposal was reviewed but unscored (12/2014).

  •    Title: Resuscitative effect of centhaquin in  hemorrhagic shock

                                                        

Agency:                                           NIH R15

Amount:                                          $447,000

Dates:                                              April 2015 – March 2017  

Principal Investigator:                   Gulati, Anil            

Co-Investigator:                             Mayer, Alejandro

Status:                                             Submitted: 6/25/2014. Grant proposal was reviewed but unscored (12/2014).

 

  •   Title: Cyanobacterial LPS and brain microglia activation  

Agency: NIH R15

Amount: $340,362 (direct), $122,500 (indirect)

                                                         Total: $462,862 For MWU: $322,500

Principal Investigator:                   Mayer, Alejandro (PI)

Co-Investigator:                             Berry, John (co-PI)

                                                         Florida International University

Status:                                             Scored 49, March 2012. Resubmitted after complete revision on 11/ 2013. Not scored.

 

 

Awards

HONORS

Editor-in-Chief, MARINE DRUGS ejournal, 1/2014 to 7/31/2018

Associate Editor, MARINE DRUGS ejournal, 8/2008 to 12/2013

President, Great Lakes Chapter of the American Society of Pharmacology and Experimental Therapeutics,  2011-2013

Vice-President, Great Lakes Chapter of the American Society of Pharmacology and Experimental Therapeutics, 2009-2010

Faculty Representative, Midwestern University, Faculty Advisory Committee, Illinois Board of Higher Education 2013-2016

Pharmacology of Natural Products Section, IUPHAR (International Union of Basic and Clinical Pharmacology), member, March 2016

 

AWARDS

July 2016.  GLC-ASPET Outstanding Contribution and Dedicated Service Award, in grateful appreciation for eight years of outstanding contribution and Dedicated Service, 2007-2015, July 2016.

June 2013.  GLC-ASPET Outstanding Service Award, in appreciation for work and dedication as President of GLC-ASPET 2011-2013.  

May 2011. The Littlejohn Faculty Award, honoring values of service, caring and commitment to Midwestern University.

More Information

PATENTS (FIRST TWO PATENTS FOR MIDWESTERN UNIVERSITY)

1.  A. Mayer, S.P. Gunasekera, S.A. Pomponi and S.H. Sennett. Anti-inflammatory uses of the Manzamines. United States Patent No.: US 6,387,916, issued May 14, 2002.

2.  A. Mayer, S.P. Gunasekera, S.A. Pomponi and S.H. Sennett. Anti-inflammatory uses of the Manzamines. United States Patent No.: US 6,602,881 issued Aug. 5, 2003.

WEBPAGE

My own research in marine pharmacology and pharmaceuticals, as well as that of the global marine pharmacology and pharmaceutical community, is highlighted at: http://marinepharmacology.midwestern.edu/. This website has received over 41,000 hits (3/5/2020), is currently # 1 in Google search engine using the key words “ marine pharmacology” and is being constantly updated with the contributions from the global marine chemistry, pharmacology and pharmaceutical research community, as well as students from the Chicago College of Pharmacy.

INVITED SEMINARS AND LECTURES (Since 2008)

I have been honored to present marine pharmaceuticals lecture/seminar presentation that covers: (1) FDA-approved marine pharmaceuticals, (2) the clinical pipeline; and, (3) the preclinical pipeline (marine natural products with antitumor and cytotoxic activity, as well as other pharmacological activities) at several scientific meetings and universities in the USA, Argentina, Brazil, Canada, France, Germany, Greece, Italy, Mexico and South Africa, as shown below.

2019    Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2019. 5th IUPHAR World Conference of the Pharmacology of Natural Products and 51st Annual Conference of the Indian Pharmacology Society, Hyderabad, India.  December 5-7, 2019.

2019   Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2019. International Summer School on Natural Products (ISSNP), Univerity of Naples “Federico II”, Naples, Italy. July 1-4, 2019.

2018   Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2018. School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Scripps Institution of Oceanograph, San Diego, California. April 25.

2017     Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2017. 10th European Marine Natural Products Meeting, Kolymbari, Crete,  Greece. September 7.

2016   Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2016. Technische Universität Bergakademie Freiberg, Freiberg, Germany. May 18.

2016       Mayer, A.M.S. Biotechnology and the Marine Pharmaceutical Pipeline in 2016. Fundación Farmacal, A.C., La Paz, Baja California Sur, Mexico. April 20-23.

2015       Mayer, A.M.S.  Biotechnology and the Marine Pharmaceutical Pipeline in 2015. National Academy of Medicine, Buenos Aires, Argentina.  June 12.

2014      Mayer, A.M.S. The global marine clinical and preclinical pipeline. 17th World Congress of Basic and Clinical Pharmacology, IUPHAR Natural Products Section Symposium, Cape Town, South Africa. July 13-18.

2014       Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Illinois. November 14.

2013       Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Molecular Therapeutics and Pharmacology, Loyola University Medical Center, Maywood, Illinois. February 20.

2012       Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Cellular and Molecular Pharmacology, Rosalind Franklin University of Medicine and Science, The Chicago Medical School, North Chicago, Illinois. August 22.

2012       Mayer, A.M.S. The global marine pharmaceutical pipeline.  OECD Global Forum on  Biotechnology:  Marine Biotechnology - Enabling Solutions for Ocean Productivity and Sustainability. Sponsored by Organization for Economic Co-operation and Development (OECD).  Wosk Centre for Dialogue, Vancouver, Canada. May 30-31.  

2012       Mayer, A.M.S. The global marine pharmacology preclinical pipeline. ASPET Symposium: “ Clinical Pipeline of Marine Pharmaceuticals: The Odyssey Continues” sponsored by The Division for Drug Discovery, Development and Regulatory affairs from the American Society of Pharmacology and Experimental Therapeutics, Experimental Biology 2012, San Diego, California. April 25.

2012       Mayer, A.M.S. Marine pharmacology and the global pharmaceutical pipeline.    Associated Colleges of the Chicago Area Spring Seminar Series. Benedictine University, Illinois. March 13.

2011      Mayer, A.M.S. The global marine pharmaceutical pipeline.  Station  Biologique de Roscoff, CNRS,  Roscoff,  France. September 1.

2011      Mayer, A.M.S. The global marine pharmaceutical pipeline. Annual Workshop on Marine  Biotechnology. Station de Biologie Marine, Museum National D’Histoire. Roscoff, France. September 1. Concarneau, France. August 31.

2011      Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Chemistry, U                                                                            University of Louisiana, Monroe, Louisiana. February.

2010  Mayer, A.M.S. Marine Biodiversity and Drug Development from Marine Sources.                                                                                           Instituto Nacional de Tecnologia Industrial, Buenos Aires, Argentina.  November 12.

2010       Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Biological Sciences, Benedictine University, Lisle, Illinois. October 13.

2010       Mayer, A.M.S. The global marine pharmaceutical pipeline. Dipartimento di Chimica delle Sostanzi Naturali, Universita Degli Studi Di Napoli Federico II, Naples, Italy.  May 21.

2010       Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois.  March 17.

2009       Mayer, A.M.S. The global marine pharmacology pipeline. Chemistry Institute of São Carlos, University of São Paulo at São Carlos, Brazil. November 23.

2009       Mayer, A.M.S. The global marine pharmacology pipeline. Experimental Biology 2009. American Society of Experimental Pharmacology and Therapeutics (ASPET) Symposium: A Renaissance in Marine Pharmacology: Preclinical Curiosity to Clinical Reality. New Orleans, Louisiana. April 19.

2009       Mayer, A.M.S.  Marine Pharmacology: FDA-approved marine drugs, and the marine clinical and preclinical pipeline. Florida International University, Graduate School and Marine Sciences Program. Miami, Florida. January 30.

2008       Mayer, A.M.S.  Marine Pharmacology: A Critique of the Preclinical and Clinical Literature. University of Puerto Rico, Rio Piedras Campus, Department of Chemistry,  San Juan, Puerto Rico. January 28.